International Immunology, Vol. 11, No. 6, 871-879,
June 1999
© 1999 Japanese Society for Immunology
CpG oligodeoxynucleotides rescue BKS-2 immature B cell lymphoma from anti-IgM-mediated growth inhibition by up-regulation of egr-1
1 Department of Microbiology and Immunology, and
2 Sanders-Brown Research Center on Aging, University of Kentucky, Lexington, KY 40536, USA
Correspondence to: S. Bondada, 329 Sanders-Brown Building, University of Kentucky, Lexington, KY 40536, USA
Cross-linking of the IgM antigen receptor on an immature B cell lymphoma (BKS-2) induces growth arrest and apoptosis. This is accompanied by down-regulation of the immediate early genes, egr-1 and c-myc, and a reduction in NF-
B activity. Anti-IgM-induced growth arrest and apoptosis of this murine B cell lymphoma were prevented by oligodeoxynucleotides (ODN) containing the CpG motif, which are also known to be stimulatory for mature and immature B cells. The CpG but not non-CpG ODN rescued BKS-2 cells from anti-IgM-mediated growth inhibition by up-regulation of egr-1 and c-myc expression as well as by restoring NF-B activity. Interestingly, changes in egr-1 expression occurred more rapidly than in c-myc expression. Also the c-myc levels remained high up to 6 h after addition of the anti-IgM, which was also the time until which the addition of CpG could be delayed without affecting its ability to provide complete protection. This CpG-induced rescue of B lymphoma cells was blocked by antisense egr-1 ODN, suggesting that the expression of egr-1 is important for the effects of CpG ODN on the growth and survival of BKS-2 cells.
Keywords: B cell lymphoma, BKS-2, CpG oligonucleotide, egr-1
3 Present address: Division of Immunotoxicology, Korea Food and Drug Administration, Seoul 122-020, Korea
Transmitting editor: A. Singer
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Ke, M. Gururajan, A. Kumar, A. Simmons, L. Turcios, R. L. Chelvarajan, D. M. Cohen, D. L. Wiest, J. G. Monroe, and S. Bondada The Role of MAPKs in B Cell Receptor-induced Down-regulation of Egr-1 in Immature B Lymphoma Cells J. Biol. Chem., December 29, 2006; 281(52): 39806 - 39818. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Khomenko, S. Szabo, X. Deng, M. R. Jadus, H. Ishikawa, K. Osapay, Z. Sandor, and L. Chen Suppression of early growth response factor-1 with egr-1 antisense oligodeoxynucleotide aggravates experimental duodenal ulcers Am J Physiol Gastrointest Liver Physiol, June 1, 2006; 290(6): G1211 - G1218. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. N. Torrero, W. G. Henk, and S. Li Regression of High-Grade Malignancy in Mice by Bleomycin and Interleukin-12 Electrochemogenetherapy Clin. Cancer Res., January 1, 2006; 12(1): 257 - 263. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gururajan, R. Chui, A. K. Karuppannan, J. Ke, C. D. Jennings, and S. Bondada c-Jun N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells Blood, August 15, 2005; 106(4): 1382 - 1391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-K. Yi, J.-G. Yoon, and A. M. Krieg Convergence of CpG DNA- and BCR-mediated signals at the c-Jun N-terminal kinase and NF-{kappa}B activation pathways: regulation by mitogen-activated protein kinases Int. Immunol., May 1, 2003; 15(5): 577 - 591. [Abstract] [Full Text] [PDF]
|
|